Reply to Kadhiravan

Clinical Infectious Diseases

Volumn 56, Issue 7, 2013, Pages 1063-

  Louie, Janice ^a   Yang, Samuel ^a   Schechter, Robert ^a  

^a VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; SIALIDASE INHIBITOR;

2009 H1N1 INFLUENZA; ANTIVIRAL THERAPY; DRUG EFFICACY; HUMAN; INFLUENZA VACCINATION; LETTER; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIVIRAL AGENTS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE;

EID: 84875023142     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1214     Document Type: Letter

References (3)

1. Kadhiravan T. Did oseltamivir really improve survival in critically ill patients with influenza A (H1N1) pdm09? Clin Infect Dis 2013; 56: 1062-3.
2. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55: 1198-204.
3. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-10 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207: 553-63.